-
Mashup Score: 2FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) - 5 month(s) ago
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284.
Source: www.businesswire.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma - 5 month(s) ago
Genmab A/S (Nasdaq: GMAB) today announced regulatory updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for
Source: www.businesswire.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨NEWS🚨 @US_FDA and @EMA_News grants Breakthrough Therapy Designation to epcoritamab for the treatment of adult pts with R/R FL who have received ≥2 lines of prior systemic therapy. This follows results from the EPCORE NHL-1 trial. Read more 👉 https://t.co/ySjZLGjiqI #MedNews https://t.co/ijHz2Q9dai
-
-
Mashup Score: 0First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK - 6 month(s) ago
NICE has recommended glofitamab as a new treatment option for adults with relapsed or refractory diffuse large B cell lymphoma after 2 or more systemic treatments in final guidance published today (17 October 2023). Today’s recommendation for its use in the NHS coincides with glofitamab receiving its licence from the Medicines and Healthcare Products Regulatory Agency (MHRA). Lymphoma is a form of blood cancer that affects the immune system. It develops from a type of white blood cell, called a lymphocyte
Source: www.nice.org.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 @NICEComms recommends glofitamab for the treatment of adult patients with relapsed or refractory diffuse large B-cell #lymphoma who have received two or more previous systemic treatments. Read more here: https://t.co/U0mjp7YHgu #lymsm #MedNews https://t.co/6znRbjhpuA
-
-
Mashup Score: 0SLS009 granted orphan drug designation by the U.S. FDA - 6 month(s) ago
On October 10, 2023, the U.S. FDA granted orphan drug designation to SLS009, a novel and highly selective CDK9 inhibitor, for the treatment of patients with AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 @US_FDA grants orphan drug designation to SLS009, a novel and highly selective CDK9 inhibitor, for the treatment of patients with AML. Read more here 👉 https://t.co/GKFLr5YPn7. #AMLsm #leusm #MedNews https://t.co/ep0WzrXkNs
-
-
Mashup Score: 4Zanubrutinib plus obinutuzumab receives positive CHMP opinion for the treatment of adult patients with R/R FL - 6 month(s) ago
Following positive data from the phase II ROSEWOOD study, zanubrutinib plus obinutuzumab receives a positive CHMP opinion for the treatment of adult patients with relapsed/refractory follicular lymphoma.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 The @EMA_News issues a positive opinion for zanubrutinib plus obinutuzumab for the treatment of adult patients with R/R FL. Read more here 👉 https://t.co/66UXkUbGtw. #lymsm #lymphoma #MedNews https://t.co/CoB7R8Gqcp
-
-
Mashup Score: 1
On October 13, 2023, the Committee for Medicinal Products for Human Use, part of the European Medicines Agency, announced the recommended marketing authorization for elranatamab.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 On October 13, 2023, the @EMA_News recommended marketing authorization of elranatamab, for the treatment of RRMM. Recommendation was based on the results from the phase II MagnetisMM-3 trial. Read more 👉 https://t.co/lAJKEwRXqT. #MMsm #MedNews https://t.co/Vma3hWgAe2
-
-
Mashup Score: 2Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE - 6 month(s) ago
/PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and…
Source: www.prnewswire.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 The Center for Drug Evaluation (#CDE) approves the global pivotal registrational phase III study of lisaftoclax, a BCL-2 inhibitor, in combination with acalabrutinib as a first-line treatment for patients with #CLL or #SLL. https://t.co/tyCnJzvou6. #lymsm #MedNews https://t.co/YwZBofmtrP
-
-
Mashup Score: 0
/PRNewswire/ — GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced…
Source: www.prnewswire.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 First patient dosed in the phase Ib/II clinical trial of GFH009, a highly selective CDK9 inhibitor, for patients with R/R PTCL. https://t.co/T7zoil99yR. #lymphoma #lymsm #medNews https://t.co/OPM08kcgIM
-
-
Mashup Score: 2Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma - Starton Therapeutics - 7 month(s) ago
Paramus, NJ – Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, announced the dosing of the first patient in the STAR-LLD Phase 1b clinical trial, which will assess the safety, efficacy and pharmacokinetics of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) for the treatment of multiple myeloma […]
Source: www.startontx.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 The first patient has been dosed in the phase Ib STAR-LLD clinical trial of low-dose lenalidomide, administered subcutaneously, for the treatment of multiple #myeloma Read more: https://t.co/gWiw67GUqI #mmsm #MedNews https://t.co/s4BRfIrxOy
-
-
Mashup Score: 0
On September 27, 2023, it was announced that the first two patients had received SMART101 in the multicenter, open-lab, dose-escalation, phase I/II ReSET-02 trial.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 NEWS 🚨 First two patients dosed in the phase I/II ReSET-02 trial to assess the safety & efficacy of SMART101, an allogeneic cell therapy, in patients with AML who have received allo-HSCT with post-transplant cyclophosphamide 👉 https://t.co/yR7jQMYrqk #AMLsm #leusm #MedNews https://t.co/YCnXRkUqGx
-
🚨 NEWS 🚨 @US_FDA grants Orphan Drug Designation to LP-284 for the treatment of adult pts with high-grade B-cell lymphoma with MYC/BCL2 rearrangements. This follows the promising anti-tumor activity of LP-284 in preclinical models. #MedNews Read more 👉 https://t.co/7wYEl4EFt6 https://t.co/vg52rixUwK